-

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.

Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY.

Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA.

About Forte

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Industry:

Forte Biosciences, Inc.

NASDAQ:FBRX
Release Versions
English

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

More News From Forte Biosciences, Inc.

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc.  (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-...

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023)...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c...
Back to Newsroom